Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates

Chang, Li‐Ling; Ma, Mark; Allmen, Heather von; Henderson, Scott C.; Harper, Kristine D.; Hornbuckle, Kenneth

doi:10.1185/03007991003771874

Cited by 5 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The percentage of nitrates co-prescribed with sildenafil, vardenafil and tadalafil was 4.1% (n=320), 1.07% (n=93) and 1.25% (n =80), respectively. This result was similar to the finding of Chang et al study that showed the co-prescribed percentages of 1.07%, 0.83% and 1.07% for sildenafil, vardenafil and tadalafil, respectively 37. Despite the overall result showing low incidence of contraindication, the need to double-check the intake of concomitant drugs is crucial for preventing severe hypotension 38…”

Section: Discussionsupporting

confidence: 88%

Drug-related problems in patients with erectile dysfunctions and multiple comorbidities

Huri¹,

Ling²,

Razack³

2017

TCRM

View full text Add to dashboard Cite

This study was conducted in a tertiary medical center in Kuala Lumpur, Malaysia. A total of 200 erectile dysfunction (ED) patients with 499 cases who had received pharmacological treatments for their ED participated in this study. Types, causes and factors associated with drug-related problems (DRPs) in ED patients with multiple comorbidities were assessed. A total of 244 DRPs with an average of 1.2±2.1 DRPs per patient were identified. Drug interaction contributed the most to DRPs occurrence. There was a significant higher risk of DRPs in patients with benign prostatic hyperplasia, lower urinary tract infection and elderly and end-stage renal disease. Early identification of types of DRPs and factors associated may enhance their prevention and management.

show abstract

Section: Discussionsupporting

confidence: 88%

Drug-related problems in patients with erectile dysfunctions and multiple comorbidities

Huri¹,

Ling²,

Razack³

2017

TCRM

View full text Add to dashboard Cite

show abstract

“…However, this study did not assess whether these participants used such medications only periodically and/or would be able to manage their medication to maintain the 24‐hour wash out period between the two agents. In the current situation, when PDE5i are prescribed by a physician, copossession rates of 2.1% [31] and 2.2% [32] have been reported in actual use studies. In addition, analysis of the manufacturer's postmarketing safety database shows that only about 1% of the almost 40,000 adverse events concerned comedication with nitrates.…”

Section: Discussionmentioning

confidence: 95%

The Ability of the General Male Public to Assess Their Suitability to Take 50-mg Sildenafil: An Assessment of the Comprehension of Patient Information Materials via Internet Survey

Symonds

Coyne²,

Margolis³

et al. 2011

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Introduction Erectile dysfunction (ED) is the most common male sexual dysfunction and has a negative impact on masculinity and self-esteem. Phosphodiesterase type 5 inhibitors, including sildenafil, are the first-line treatment option for ED. Providing appropriate information regarding suitability for using sildenafil is important. Aim The purpose of this study was to assess whether a broad spectrum of men could appropriately evaluate their suitability for 50-mg sildenafil after reviewing patient information materials. Main Outcome Measures Patient information (Pack) on appropriate use of 50-mg sildenafil and patient information leaflet (PIL), a Web survey including demographics, self-assessed suitability for sildenafil use, and suitability screener. Methods A randomly selected, population-representative Web-based panel of males in the UK was recruited for this study. Eligible men answered a brief sociodemographic questionnaire and then were presented with the Pack. If a participant desired additional information, he could also review the PIL. The participants then rated the Pack and PIL (if reviewed), self-assessed their suitability for sildenafil use, and completed a previously validated screener for suitability. Results A total of 1,275 men aged 40 and above were included in these analyses; the mean age was 57.8 ± 9.9 years. A total of 1,054 men reported ED; 517 men (40.5%) deemed themselves suitable for sildenafil; 504 men (39.6%) deemed themselves unsuitable; and 254 (19.9%) were unsure. The concordance rate between screener-assessed suitability and self-assessed suitability was 70.9% (95% confidence interval [CI] = 68.1–73.7%). When accounting for men who would not take sildenafil even though they were suitable or would seek additional information from a healthcare professional prior to using sildenafil, the concordance rate was 84.2% (95% CI = 82.2–86.2%). Conclusion The results of this study suggest that men in the general population are capable of using written sildenafil patient education materials to accurately assess their suitability for treatment with 50-mg sildenafil.

show abstract

Phosphodiesterase Type 5 Inhibitors and Oral Nitrates in Male Patients with Ischemic Heart Disease

Morrisette

Dunn

2023

Curr Cardiol Rep

View full text Add to dashboard Cite

Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates

Cited by 5 publications

References 14 publications

Drug-related problems in patients with erectile dysfunctions and multiple comorbidities

Drug-related problems in patients with erectile dysfunctions and multiple comorbidities

The Ability of the General Male Public to Assess Their Suitability to Take 50-mg Sildenafil: An Assessment of the Comprehension of Patient Information Materials via Internet Survey

Phosphodiesterase Type 5 Inhibitors and Oral Nitrates in Male Patients with Ischemic Heart Disease

Contact Info

Product

Resources

About